Sionna Therapeutics, Inc. (SION)

Sionna Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Selling, General & Admin	13.27	9.71	6.77
Research & Development	57.29	40.63	34.61
Operating Expenses	70.56	50.33	41.37
Operating Income	-70.56	-50.33	-41.37
Interest & Investment Income	8.17	2.77	1.13
Other Non Operating Income (Expenses)	0.7	0.3	-
Pretax Income	-61.69	-47.26	-40.24
Net Income	-61.69	-47.26	-40.24
Net Income to Common	-61.69	-47.26	-40.24
Shares Outstanding (Basic)	4	3	3
Shares Outstanding (Diluted)	4	3	3
Shares Change (YoY)	31.56%	13.80%	-
EPS (Basic)	-15.99	-16.11	-15.61
EPS (Diluted)	-15.99	-16.11	-15.61
Free Cash Flow	-52.81	-44.82	-37.94
Free Cash Flow Per Share	-13.69	-15.28	-14.72
EBITDA	-69.89	-49.75	-41.25
D&A For EBITDA	0.67	0.58	0.12
EBIT	-70.56	-50.33	-41.37

Updated Mar 20, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q